Which humanoid robot manufacturers can I invest in?

Public vs private: the humanoid cohort

The major humanoid robot manufacturers in 2026 split roughly along a public-versus-private dimension that matters for direct equity exposure. The publicly-traded humanoid-cohort exposure:

• UBTech Robotics: publicly traded on the Hong Kong Stock Exchange. The only major humanoid pure-play available to general investors via standard equity markets. Walker S2 industrial-deployment focus with BYD/Geely/Foxconn pilots.
• Tesla: NASDAQ-listed. The Optimus humanoid is one product line within Tesla's broader portfolio (autonomous vehicles, energy products, automotive); investors get diluted humanoid exposure alongside the rest of Tesla's business.
• Hyundai Motor Group: Korea Exchange (KRX)-listed. Boston Dynamics is a subsidiary. Investors get diluted humanoid exposure alongside Hyundai's automotive and broader business.
• Mobileye: NASDAQ-listed. Mentee Robotics is a Mobileye subsidiary following the January 2026 ~$900M acquisition. Investors get humanoid exposure alongside Mobileye's autonomous-vehicle perception business.

The privately-held humanoid-cohort major makers:

• Figure AI: private; reportedly multi-billion-dollar valuation per recent funding rounds. Strategic investors include BMW Group, Microsoft, OpenAI, Nvidia.
• 1X Technologies: private; OpenAI-backed plus additional venture capital. Norwegian-American structure.
• Apptronik: private; $520M Series A in February 2026 at $5.5B valuation; lead investors Google and Mercedes-Benz.
• Agility Robotics: private; investors include DCVC, Playground Global, and broader venture syndicate.
• Sanctuary AI: private; Canadian.

For these private makers, direct equity exposure is limited to venture-stage participation (accredited investors with deal flow), secondary-market transactions (where available; structurally complex), or waiting for a future IPO or acquisition.

What "investing in humanoid robots" actually means

The query class "best humanoid manufacturer to invest in" surfaces several different actual intents per DEPLOY's verified-vs-claimed framework:

• Direct equity in pure-play humanoid maker: largely limited to UBTech. Other public options are diluted humanoid exposure inside broader-business companies.
• Diversified humanoid sector exposure via ETFs: BOTZ (Global X Robotics & Artificial Intelligence ETF), ROBO (ROBO Global Robotics & Automation Index ETF), and similar sector funds provide indexed exposure to robotics and AI broadly. Humanoid pure-plays are a fraction of the holdings; the funds include broader robotics + automation companies.
• Venture-stage exposure to US humanoid makers: accessible to accredited investors via direct venture deals, secondary marketplace transactions, or pre-IPO funds.
• Strategic-investor exposure: BMW, Microsoft, OpenAI, Nvidia, Mercedes-Benz, Google, and Hyundai all hold strategic positions in humanoid makers; investing in those strategic partners produces fractional exposure.

The honest framework reading: direct, public, pure-play humanoid exposure is a small set in 2026 (essentially UBTech). The broader humanoid investment thesis requires diluted or venture-stage participation.

What DEPLOY can verify and what we cannot

Per DEPLOY's registry-as-source-of-truth discipline:

• Verified: corporate structure (public vs private), HQ location, founding details, disclosed funding rounds and valuations where publicly reported, parent-company relationships, executive leadership.
• Claimed: forward-looking financial projections, path-to-profitability timelines, valuation multiples, IPO timing for private companies.
• Cap-flagged: private-company financial state at the depth public companies are required to disclose. The verification asymmetry between public and private cohort members is structural; investors should evaluate this difference explicitly.

For investors evaluating verification posture as a proxy for investment quality: publicly-listed makers carry the verification chain that quarterly audited filings provide. Private makers carry the verification posture that strategic-investor due diligence and founder track records provide. The two verification surfaces are different shapes; neither is inherently better.

What DEPLOY is not

DEPLOY is an editorial publication documenting verified-versus-claimed positions across the humanoid robotics market. DEPLOY is not an investment advisor. The verification work documented across this site is editorial discipline applied to maker claims about products, deployments, and capabilities. It is not a financial-advisory product, does not constitute investment recommendations, and is not a substitute for due diligence with qualified financial professionals.

For investors evaluating humanoid exposure, the framework reading is: maker verification posture is one editorial signal among many financial-investment considerations. Track record, financial sustainability, competitive position, regulatory environment, and capital structure all matter alongside the verification framework DEPLOY operates.

Where to go for context

For canonical institutional depth on each maker (founding history, funding rounds, parent-company relationships, source-depth verification), see the per-maker registry records: UBTech Robotics, Tesla, Hyundai Motor Group, Figure AI, 1X Technologies, Apptronik, Agility Robotics, Sanctuary AI, Mentee Robotics.

For geographic and cohort context, see which humanoid robots are American vs Chinese. For the broader market overview, see the leading humanoid robot makers.